Biomarkers Market by Types (Safety, Efficacy, and Validation), Application Areas (Diagnostic, Drug Development, Personalized Medicine, and Others), Diseases (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, and Others), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global biomarkers market was valued at USD 46.4 billion in 2019 and is projected to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the high occurrence of life-threatening diseases such as cancer and tumors and growing investment in the research and study initiatives.
Biomarkers are measurements for the performance of clinical assessments such as cholesterol levels or blood pressure. Biomarkers can also be used to monitor, predict and study health states in patients or individuals in general for the accurate therapeutic treatments. Every biological system from the metabolic system, cardiovascular system to the immune system has their own specific biomarkers. Most of these biomarkers can be measured relatively easily and can be studied separately to find treatment plans and hygiene. For instance, a patient who wants to undergo a health checkup can include heart rate measurement, triglycerides, fasting glucose levels, blood pressure, and cholesterol. Different measurements such as the body mass index or BMI to evaluate the weight of the patient and waist-to-hip ratio are used for the treatment of diseases such as obesity.
World Health Organization (WHO) conducted a survey in 2018 regarding the immune to disease system and found that 60% of the burden of diseases are likely to be chronic in nature. This contributes heavily to the global biomarkers market. The COVID-19 pandemic has reduced the growth of the global biomarkers market initially. However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. Basically, a patient of blood pressure or cholesterol was more susceptible to the COVID-19 virus than that of a healthy person. This steered to hospitals, clinics, and healthcare laboratories to focus more on biomarkers for the prevention and treatment of diseases and this led to its market growth. Biomarkers are the key indicators that provide certain characteristics for checking disease conditions or identification of diseases infection. Biomarkers are considered to be easy and safe to measure, cost efficient, and modifiable with the required treatments.
Market Trends, Drivers, Restraints, and Opportunities
- The major driver for the global biomarkers market is the extensive research combined with the technological advancements being utilized for development for clinics and healthcare centers related to biomarker diagnostics.
- Surge in chronic diseases such as cancer, cardiovascular disorders, and diabetes in a global scale because of unhealthy diet, lack of exercise, and sedentary lifestyle are projected to boost the market.
- Wide applications for various medical research and rising investment for researchers to conduct novel studies for advanced treatment options and further precise diagnosis are acting as major drivers for the global biomarkers market.
- Expensive research process and lack of advanced healthcare facilities for the development of studies related to biomarkers especially in developing regions are key challenges that can hamper the market growth.
- Biomarker signatures and other nascent developments have significantly increased the rate of treatment for both neurological and cardiovascular diseases, which result in the early diagnosis, rapid drug treatment, and non-invasive testing. This can offer several opportunities for the market expansion.
Scope of the Report
The report on the global biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (Safety, Efficacy, and Validation), Application Areas (Diagnostic, Drug Development, Personalized Medicine, and Others), and Diseases (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
| Key Players Covered in the Report | Abbott Laboratories; Qiagen; F. Hoffmann-La Roche AG; Thermo Fisher Scientific, Inc; Siemens Healthcare Private Limited; Agilent Technologies, Inc; Bio-Rad Laboratories, Inc; Johnson & Johnson Services, Inc; and Epigenomics AG |
Global Biomarkers Market Segment Insights
Safety biomarkers to constitute a large market share
On the basis of types, the global biomarkers market is segmented into safety, efficacy, and validation. The safety segment is expected to constitute a large market share in the coming years owing to the rapid increase in usage and adoption of the product drug discovery within the development sector. The safety biomarker finds applications in various premedical trials for the selection of candidates displaying tolerance towards the drug. These processes and studies carry a number of advantages such as reduction of both cost and time, thereby, increasing efficiency and safety to use from the drug development perspective.
On the other hand, the validation segment is anticipated to register a high CAGR during the forecast period owing to the extensive application of product type in the pharmaceutical industry. The validation biomarkers also help in the prediction of therapeutic failures by identifying the non-responders with specific distinct genetic profiles.
Drug development segment to hold a key share
Based on application areas, the market is divided into diagnostic, drug development, personalized medicine, and others. The drug development is projected to hold a large market share in the coming years since the drug manufacturing companies are completely focused on the extensive research and development initiatives used for the creation of targeted therapeutics. However, the personalized medicines segment is anticipated to show a high CAGR in the global biomarkers market due to the increasing consumer awareness of personalized medicine and wide adoption of medicines.
Cancer segment is anticipated to exhibit a robust CAGR
Based on diseases, the global biomarkers market is segmented into cancer, cardiovascular diseases, neurological diseases, immunological diseases and others. The cancer segment is anticipated to exhibit a robust CAGR during the forecast period owing to the increasing demand for rapid and accurate diagnostic tools along with the sharp growth of requirements on the global scale. Growing considerable demand for various personalized medicines and increasing adoption of strategic alliances between pharmaceutical and diagnostic companies for cancer treatment devices are expected to propel the segment growth. On the other hand, the cardiovascular disease segment is anticipated to expand at a substantial CAGR during the forecast period owing to wide conduction of successful research studies and diagnostics done in this field.
North America is anticipated to dominate the market
In terms of regions, the market is classified as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America held over 35.4% of the global biomarker market revenue share in 2020 and is anticipated to continue its domination in the market in the coming years. The regional market growth is driven by the increasing disease burden coupled with proactive Government initiatives. Moreover, the presence of major market players and favorable regulatory policies from government bodies present key factors driving the regional market growth. However, the market in Asia Pacific is projected to register a lucrative CAGR during the forecast period, 2021-2028. Some factors fueling the regional market growth includes the strategic initiatives taken several regional governments for the co-development of products, rising research and development investments, and reduction of cost in trials.
Segments
Segments Covered in the ReportThe global biomarkers market has been segmented in terms of
Types
- Safety
- Efficacy
- Validation
- Diagnostic
- Drug Development
- Personalized Medicine
- Others
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific, Inc
- Siemens Healthcare Private Limited
- Agilent Technologies, Inc
- Bio-Rad Laboratories, Inc
- Johnson & Johnson Services, Inc
- Epigenomics AG
Competitive Landscape
Some of the major players in the global biomarkers market are Abbott Laboratories; Qiagen; F. Hoffmann-La Roche AG; Thermo Fisher Scientific, Inc; Siemens Healthcare Private Limited; Agilent Technologies, Inc; Bio-Rad Laboratories, Inc; Johnson & Johnson Services, Inc; and Epigenomics AG. Most of these players are currently engaged in strategic initiatives including mergers & acquisitions, promoting awareness, and new product development to increase their market position. F. Hoffmann-La Roche AG, in 2017, received the approval from the US Food and Drug Administration or the FDA for the biomarker assay designated for bladder cancer.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biomarkers Market - Supply Chain
4.5. Global Biomarkers Market Forecast
4.5.1. Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Biomarkers Market Absolute $ Opportunity
5. Global Biomarkers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Biomarkers Market Size and Volume Forecast by Types
5.3.1. Safety
5.3.2. Efficacy
5.3.3. Validation
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Biomarkers Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Biomarkers Market Size and Volume Forecast by Applications
6.3.1. Diagnostic
6.3.2. Drug Development
6.3.3. Personalized Medicine
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Biomarkers Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Biomarkers Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Biomarkers Demand Share Forecast, 2019-2026
8. North America Biomarkers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Biomarkers Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Biomarkers Market Size and Volume Forecast by Types
8.4.1. Safety
8.4.2. Efficacy
8.4.3. Validation
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Biomarkers Market Size and Volume Forecast by Applications
8.7.1. Diagnostic
8.7.2. Drug Development
8.7.3. Personalized Medicine
8.7.4. Others
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Biomarkers Demand Share Forecast, 2019-2026
9. Latin America Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Biomarkers Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Biomarkers Market Size and Volume Forecast by Types
9.4.1. Safety
9.4.2. Efficacy
9.4.3. Validation
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Biomarkers Market Size and Volume Forecast by Applications
9.7.1. Diagnostic
9.7.2. Drug Development
9.7.3. Personalized Medicine
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Biomarkers Demand Share Forecast, 2019-2026
10. Europe Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Biomarkers Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Biomarkers Market Size and Volume Forecast by Types
10.4.1. Safety
10.4.2. Efficacy
10.4.3. Validation
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Biomarkers Market Size and Volume Forecast by Applications
10.7.1. Diagnostic
10.7.2. Drug Development
10.7.3. Personalized Medicine
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Biomarkers Demand Share Forecast, 2019-2026
11. Asia Pacific Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Biomarkers Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Biomarkers Market Size and Volume Forecast by Types
11.4.1. Safety
11.4.2. Efficacy
11.4.3. Validation
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Biomarkers Market Size and Volume Forecast by Applications
11.7.1. Diagnostic
11.7.2. Drug Development
11.7.3. Personalized Medicine
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Biomarkers Demand Share Forecast, 2019-2026
12. Middle East & Africa Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Biomarkers Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Biomarkers Market Size and Volume Forecast by Types
12.4.1. Safety
12.4.2. Efficacy
12.4.3. Validation
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Biomarkers Market Size and Volume Forecast by Applications
12.7.1. Diagnostic
12.7.2. Drug Development
12.7.3. Personalized Medicine
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Biomarkers Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Biomarkers Market: Market Share Analysis
13.2. Biomarkers Distributors and Customers
13.3. Biomarkers Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Abbott Laboratories
13.4.2. F. Hoffmann-La Roche AG
13.4.3. Thermo Fisher Scientific, Inc
13.4.4. Siemens Healthcare Private Limited
13.4.5. Agilent Technologies, Inc
13.4.6. Bio-Rad Laboratories, Inc
The global biomarkers market has been segmented in terms of
Types
- Safety
- Efficacy
- Validation
- Diagnostic
- Drug Development
- Personalized Medicine
- Others
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific, Inc
- Siemens Healthcare Private Limited
- Agilent Technologies, Inc
- Bio-Rad Laboratories, Inc
- Johnson & Johnson Services, Inc
- Epigenomics AG
Some of the major players in the global biomarkers market are Abbott Laboratories; Qiagen; F. Hoffmann-La Roche AG; Thermo Fisher Scientific, Inc; Siemens Healthcare Private Limited; Agilent Technologies, Inc; Bio-Rad Laboratories, Inc; Johnson & Johnson Services, Inc; and Epigenomics AG. Most of these players are currently engaged in strategic initiatives including mergers & acquisitions, promoting awareness, and new product development to increase their market position. F. Hoffmann-La Roche AG, in 2017, received the approval from the US Food and Drug Administration or the FDA for the biomarker assay designated for bladder cancer.
Our Clients
Related Reports
Some other reports from this category!
